T. Rowe Price Investment Management, Inc. Erasca, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Erasca, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 16,830,856 shares of ERAS stock, worth $42.9 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
16,830,856
Previous 7,374,359
128.23%
Holding current value
$42.9 Million
Previous $17.4 Million
164.01%
% of portfolio
0.03%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding ERAS
# of Institutions
140Shares Held
229MCall Options Held
28.7KPut Options Held
117K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$49.4 Million2.85% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$41.4 Million4.58% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$35.1 Million1.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$33.9 Million0.0% of portfolio
-
Arch Venture Management, LLC Chicago, IL11.1MShares$28.2 Million18.15% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $311M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...